相关实验视频
Updated: Feb 4, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
1.3K
成年人中肥胖药物和获得的下丘脑肥胖症:两例病例经验
Henry Lang1, Madisen F Dorand2, Mahnooor Hassan2
1Oklahoma State University College of Osteopathic Medicine, 1111W 17th Street, Tulsa, OK, 74107, United States.
Obesity pillars
|February 2, 2026
概括
基于蒂尔泽帕提德的疗法在治疗成年人获得的下丘脑肥胖症 (HO) 中表现有前途. 与芬特明或芬特明/托皮拉酸联合治疗导致两名HO患者显著减肥和改善健康状况.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 神经学 神经学
背景情况:
- 由于缺乏成熟的成年人药物治疗结果,获得的下丘脑肥胖症 (HO) 构成了重大的临床挑战.
- HO的特点是由于下丘脑损伤导致的大量体重增加,通常是中枢神经系统瘤治疗的次要原因.
研究的目的:
- 为了评估药物治疗的临床结果,在成年患者获得的下丘脑肥胖症.
- 评估基于蒂尔泽帕提德的组合疗法的有效性,以控制HO患者的体重和并发症.
主要方法:
- 对两名被诊断患有获得的下丘脑肥胖症的患者进行了回顾性图表审查.
- 系统分析了患者关于体重变化和治疗干预措施的数据.
主要成果:
- 两名患有HO的患者在使用提尔泽帕提德与芬特明或芬特明/托皮拉玛结合后,实现了显著的体重减轻.
- 案例1:提尔泽帕提德加上芬特明,在7个月内减轻12.26%的体重.
- 案例2:提尔泽帕提德加上胺/托皮拉在11个月内减轻了35.10%的体重,同时改善了高血压和阻塞性睡眠呼吸暂停.
结论:
- 基于蒂尔泽帕提德的组合疗法与HO的成年人中临床上有意义的体重减轻和并发症改善有关.
- 这些发现表明多式联络治疗策略对获得HO的潜在益处,并需要进一步调查.
相关概念视频
Obesity
1.3K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.3K
Drug Dosing: Obese Patients
263
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
263
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
282
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
282
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
184
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
184
Hypothalamic-Pituitary Axis
66.1K
The response to stress—be it physical or psychological, acute or chronic—involves activation of the Hypothalamic-Pituitary-Adrenal (HPA) axis. The HPA axis is part of the neuroendocrine system because it involves both neuronal and hormonal communication. Its function is to regulate homeostatic systems—metabolic, cardiovascular, and immune—providing the necessary means to respond to a stressor.
66.1K
Inhaled Medications
801
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
801

